Monitoring sirolimus levels: How does it affect the immunoassay used?;Monitorización de niveles de sirolimus: ¿cómo afecta el inmunoensayo utilizado?

Nefrologia

Volumn 31, Issue 3, 2011, Pages 359-361

  Marin Casino M ^a   Crespo, M ^a   Mateu de Antonio, J ^a   Pascual, J ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

BLOOD; DRUG MONITORING; FEMALE; HUMAN; IMMUNOASSAY; LETTER; MALE; METHODOLOGY; MIDDLE AGED;

DRUG MONITORING; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 79959328126     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Feb.10857     Document Type: Letter

References (12)

1. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005;44(8):769-86.
2. Johnson RN, Sargon R, Woollard G, Davidson J. An evaluation of the Abbott IMx sirolimus assay in relation to a high-performance liquid chromatography-ultraviolet method. Ann Clin Biochem 2005;42(Pt 5):394-7.
3. Zochowska D, Bartlomiejczyk I, Kaminska A, Senatorski G, Paczek L. High-performance liquid chromatography versus immunoassay for the measurement of sirolimus: comparison of two methods. Transplant Proc 2006;38(1):78-80.
4. Morris RG, Salm P, Taylor PJ, Wicks FA, Theodossi A. Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther Drug Monit 2006;28(2):164-8.
5. Scholer A, Von Rickenbach R, Faffa G, Vetter B. Evaluation of a microparticle enzyme immunoassay for the measurement of sirolimus in whole blood (Abbott IMx sirolimus). Clin Lab 2006;52(7-8):325-34.
6. Bargnoux AS, Bonardet A, Chong G, Garrigue V, Deleuze S, Dupuy AM, et al. Evaluation of an immunoassay (Abbott-IMX Analyzer) allowing routine determination of sirolimus: comparison with LC-MS method. Transplant Proc 2006;38(7):2352-3.
7. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000;14(2):97-109.
8. Holt D, Jones K, Johnston A. An imunoassay for measurement of sirolimus. Clin Chem 1998;44(Suppl):A94.
9. Courtais C, Dupuy AM, Bargnoux AS, Pageaux GP, Fegueux N, Mourad G, et al. Evaluation of two sirolimus assays using the ARCHITECT-i1000((R)) CMIA or RxL(R)) ACMIA methods in comparison with the IMx(R)) MEIA method. Clin Chem Lab Med Jul 29.10. http://www.bioanalytics.co.uk/pt/pt_informati on.html (accessed 01 July 2010).
10. Schmid RW, Lotz J, Schweigert R, Lackner K, Aimo G, Friese J, et al. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer. Clin Biochem 2009;42(15):1543-8.
11. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisoriesavis/ prof/2009/rapamune_4_hpc-cps-eng. pdf (accessed 1 September 2010).
12. http://www.uch.edu/docs/pdf/2009-11-13 Test Update - Immunosuppressant Tests.pdf (accessed 1 September 2010)